View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports

Pulse Biosciences Inc: 1 director

A director at Pulse Biosciences Inc sold 50,000 shares at 17.420USD and the significance rating of the trade was 81/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years c...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: December 18, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: December 14, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

AMREP Reports Second Quarter Fiscal 2025 Results

AMREP Reports Second Quarter Fiscal 2025 Results HAVERTOWN, Pa., Dec. 13, 2024 (GLOBE NEWSWIRE) -- AMREP Corporation (NYSE:AXR) today reported net income of $4,042,000, or $0.75 per diluted share, for its 2025 fiscal second quarter ended October 31, 2024 compared to net income of $1,108,000, or $0.21 per diluted share, for the same period of the prior year. For the first six months of 2025, AMREP had net income of $8,106,000, or $1.51 per diluted share, compared to net income of $2,454,000, or $0.46 per diluted share, for the same period of 2024. Revenues were $11,906,000 and $30,997,000 ...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: December 7, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

Monthly Insider Special Screens: December 1, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

PSEC PROSPECT CAPITAL CORPORATION
OPK OPKO HEALTH INC.
NMFC NEW MOUNTAIN FINANCE CORPORATION
MCHX MARCHEX INC. CL B
LTRX LANTRONIX INC.
HSII HEIDRICK & STRUGGLES INTERNATIONAL INC.
HASI
I3N HANNON ARMSTRONG SUSTAINABLE INFRASTRUCTURE CAPITAL INC.
EXAS CHART INDUSTRIES INC.
EL EXACT SCIENCES CORPORATION
CROX ESTEE LAUDER COMPANIES INC. CLASS A
CNC CROCS INC.
BRKR CENTENE CORPORATION
APPS BRUKER CORPORATION
AVNW DIGITAL TURBINE
AIN AVIAT NETWORKS
CMCO ALBANY INTERNATIONAL CORP. CLASS A
ENPH COLUMBUS MCKINNON CORPORATION
HTLD ENPHASE ENERGY INC.
SACH HEARTLAND EXPRESS INC.
DMLP SACHEM CAPITAL
HLNE DORCHESTER MINERALS L.P.
ANGI HAMILTON LANE INCORPORATED CLASS A
MBIN ANGI INC. CLASS A
LILA MERCHANTS BANCORP
FF LIBERTY LATIN AMERICA A
MEC FIRST MINING GOLD
NOVA MAYVILLE ENGINEERING
GRWG SUNNOVA ENERGY INTERNATIONAL
PCB GROWGENERATION
CLDX PACIFIC CITY FINANCIAL CORP
FBRX CELLDEX THERAPEUTICS INC.
TFC FORTE BIOSCIENCES INC
ONEW TRUIST FINANCIAL CORP
ARRY ONEWATER MARINE
SSSS ARRAY TECHNOLOGIES
ABCL SUTTER ROCK CAPITAL CORP.
CSU ABCELLERA BIOLOGICS
IMNM CAPITAL SENIOR LIVING
GRNT IMMUNOME
PFBX GRANIT SKOPKE
TRIN PEOPLES FINANCIAL CORP. (MISSISSIPPI)
ZETA TRINITY CAPITAL INC
RWAY ZETA GLOBAL HLDGS CORP
ANTX RUNWAY GROWTH FINANCE CORP
NXGL AN2 THERAPEUTICS INC
CALC NEXGEL INC
DBD CALCIMEDICA INC.
CATX DIEBOLD NIXDORF INCORPORATED
MDRR PERSPECTIVE THERAPEUTICS
PDYN INC.
DC MEDALIST DIVERSIFIED REIT INC.
AGFY SARCOS TECHNOLOGY AND ROBOTICS CORP
ETS DAKOTA GOLD CORP.
AGRIFY CORPORATION
ENTERASYS NETWORKS INC /DE/
Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: November 30, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: November 23, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

 PRESS RELEASE

Erasca Reports Third Quarter 2024 Business Updates and Financial Resul...

Erasca Reports Third Quarter 2024 Business Updates and Financial Results Positive preliminary Phase 1b data in SEACRAFT-1 NRASm melanoma cohort bolsters conviction in ongoing SEACRAFT-2 registrational trial; Stage 1 randomized data expected in 2025 Strong execution across potentially best-in-class RAS targeting franchise; planned IND submissions on track Robust balance sheet with cash, cash equivalents, and marketable securities of $463 million as of September 30, 2024, is expected to fund operations into H1 2027 SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Eras...

 PRESS RELEASE

Shoals Technologies Group, Inc. Reports Financial Results for Third Qu...

Shoals Technologies Group, Inc. Reports Financial Results for Third Quarter 2024 – Secures Favorable Initial Ruling in ITC Case Against Voltage, LLC – – Quarterly Revenue of $102.2 million – – Gross Profit Percentage of 24.8% and Adjusted Gross Profit Percentage of 37.9% – – Net Loss of $0.3 million – – Adjusted EBITDA of $24.5 million – – Raises Midpoint of Full-Year Revenue Outlook – PORTLAND, Tenn., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Shoals Technologies Group, Inc. (“Shoals” or the “Company”) (Nasdaq: SHLS), a leading provider of electrical balance of system (“EBOS”) s...

 PRESS RELEASE

Erasca to Present at Upcoming Investor Conferences

Erasca to Present at Upcoming Investor Conferences SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that management will participate in the following investor conferences and will also participate in one-on-one investor meetings. Guggenheim Securities Healthcare Innovation Conference (November 11 – 13, 2024)Location: InterContinental Hotel, Boston, MAFormat: Fireside Chat Date a...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: December 2, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Shoals Technologies Group, Inc. Announces Participation in Upcoming In...

Shoals Technologies Group, Inc. Announces Participation in Upcoming Investor Events PORTLAND, Tenn., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Shoals Technologies Group, Inc. (“Shoals”), a global leader in electrical balance of system (“EBOS”) solutions for the energy transition market, announced today its participation in the following upcoming investor events: November 14, 2024: Jefferies Virtual Fireside Chat Shoals’ CEO Brandon Moss, CFO Dominic Bardos, and VP of Finance and Investor Relations Matt Tractenberg will participate in a fireside chat with covering analyst Julien Dumoulin-Smith....

 PRESS RELEASE

Erasca Announces Strong Momentum for Naporafenib and RAS Targeting Fra...

Erasca Announces Strong Momentum for Naporafenib and RAS Targeting Franchise Positive preliminary Phase 1b SEACRAFT-1 data for naporafenib plus trametinib reinforce therapeutic potential in NRASm melanoma and further support ongoing Phase 3 SEACRAFT-2 trial SEACRAFT-2 has potential for approval based on alignment with US and European regulatory agencies on path for tissue-specific indication in melanoma; Stage 1 randomized data expected in 2025 Rapid progress across RAS targeting franchise; planned IND submissions remain on track Erasca to host investor event today at 8:30 AM Eastern Tim...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: October 19, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: October 16, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch